Last mentioned: Mar 26, 2026
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Discovery Phase Begins
Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
Lead Plaintiff Deadline
Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
Lead Plaintiff Deadline (Est.)
Typical 60-day window for investors to petition the court to lead the consolidated class action.
Lead Plaintiff Deadline (Estimated)
Expected window for investors to file motions to lead the class actions against RARE, MREO, and NAVAN.
Q4 2026 Earnings Release
Official release of fiscal year-end financial results and SEC filing.
Earnings Conference Call
Management discussed AI integration and 2027 guidance with analysts.
Market Reaction
Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
Investor Alerts Issued
Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
Investor Alerts Issued
Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
Coordinated Legal Alerts
Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
Director Election Filing
Navan filed an 8-K regarding the election of new directors to the board.
Navan (NAVN) concluded its fiscal 2026 with a Q4 earnings call highlighting the successful scaling of its AI-powered expense management platform. CEO Ariel Cohen and VP of Investor Relations Ryan Burkart detailed the company's progress in capturing global enterprise market share while moving toward GAAP profitability.
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Pomerantz Law Firm has initiated a series of investigations into seven companies, including Snowflake and Navan, regarding potential securities fraud and unlawful business practices. These probes target firms across the technology, finance, and healthcare sectors, signaling a heightened period of legal scrutiny for public entities.